MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)

Exclusion Criteria

• •1. Disease diagnosis of acute promyelocytic leukemia
• •2. Previously treated malignancies other than the current disease, except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancer from which the subject has been disease-free for at least 5 years at the trial entry
• •3. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
• •4. Major surgery, other than diagnostic surgery, within 4 weeks prior to the trial entry, without complete recovery
• •5. Percutaneous coronary intervention conducted within 6 months prior to the trial entry for cardiac infarction or angina pectoris
• •6. Seizure disorders requiring anticonvulsant therapy
• •7. Taking a medication that prolongs QT interval and has a risk of Torsades de Pointes，or a history of long QT syndrome
• •8. Medical history of difficulty swallowing, malabsorption or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the tested product
• •9. Participation in an investigational drug or device trial within 4 weeks prior to the trial entry
• •10. Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
• •11. Recent venous thrombosis (including deep vein thrombosis or pulmonary embolism within 1 year of study)
• •12. History of upper gastrointestinal hemorrhage, peptic ulcer disease, or bleeding diathesis
• •13. Subject is pregnant (positive serum beta human chorionic gonadotropin \[β-HCG\] test at screening) or is currently breast-feeding, their partner anticipates becoming pregnant/impregnating during the trial or within 6 months after receiving the last dose of trial treatment
• •14. Concomitant disease or condition that could interfere with the conduct of the trial, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this trial
• •15. Unwillingness or inability to comply with the trial protocol for any reason
• •16. Legal incapacity or limited legal capacity
• •17. Cardiac disease with New York Heart Association (NYHA) Class III or IV, including congestive heart failure, myocardial infarction within 6 months prior to the trial entry, unstable arrhythmia, or symptomatic peripheral arterial vascular